Loading…
Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke
Edaravone dexborneol has been reported as an effective neuroprotective agent in the treatment of acute ischemic stroke (AIS). This study aimed at investigating the impact of edaravone dexborneol on functional outcomes and systematic inflammatory response in AIS patient. All participants were recruit...
Saved in:
| Published in: | BMC neurology 2024-06, Vol.24 (1), p.209-8, Article 209 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c445t-348545505927d9e2efcba004980e74c0dcdf013a452589abbfe69546946b2d433 |
| container_end_page | 8 |
| container_issue | 1 |
| container_start_page | 209 |
| container_title | BMC neurology |
| container_volume | 24 |
| creator | Chen, Wenxia Zhang, Hanqing Li, Zhenzhen Deng, Qiwen Wang, Meng Chen, Yingbin Zhang, Yuan |
| description | Edaravone dexborneol has been reported as an effective neuroprotective agent in the treatment of acute ischemic stroke (AIS). This study aimed at investigating the impact of edaravone dexborneol on functional outcomes and systematic inflammatory response in AIS patient.
All participants were recruited from the AISRNA study (registered 21/11/2019, NCT04175691 [ClinicalTrials.gov]) between January 2022 and December 2022. The AIS patients were divided into two groups based on whether they received the treatment of edaravone dexborneol (37.5 mg/12 hours, IV) within 48 h after stroke onset. Inflammatory response was determined by detecting levels of cytokines (interleukin-2 [IL-2], IL-4, IL-5, IL-8, IL-6, IL-10, IL-12p70, IL-17, tumor necrosis factor-α [TNF-α], interferon-γ [IFN-γ], IFN-α, and IL-1β) within 14 days after stroke onset.
Eighty-five AIS patients were included from the AISRNA study. Patients treated with edaravone dexborneol showed a significantly higher proportion of modified Rankin Scale score |
| doi_str_mv | 10.1186/s12883-024-03712-1 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_791711bf2ea1483ca6fd43edb7b200a2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A798491767</galeid><doaj_id>oai_doaj_org_article_791711bf2ea1483ca6fd43edb7b200a2</doaj_id><sourcerecordid>A798491767</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-348545505927d9e2efcba004980e74c0dcdf013a452589abbfe69546946b2d433</originalsourceid><addsrcrecordid>eNptkk9v1DAQxSMEoqXwBTigSFy4pPhfYvuEqqpApUpc4GxN7PFuShIvtrPQb493t5QuQjk4Gb_5RTPvVdVrSs4pVd37RJlSvCFMNIRLyhr6pDqlQtKGcSmfPno_qV6kdEsIlUrQ59UJV5qwTtPTanvlPdqc6uBrdBBhG2asHf7qQ5wxjHWYa7_MNg9hhvK1ZBsmrGF29TD7EaYJcoh3dcS0CXPCUq03kAecC_PnkNc12CWXcrJrnAZbpxzDd3xZPfMwJnx1f55V3z5efb383Nx8-XR9eXHTWCHa3HChWtG2pNVMOo0Mve2BEKEVQSkscdZ5QjmIlrVKQ9977HQrOi26njnB-Vl1feC6ALdmE4cJ4p0JMJh9IcSVgZgHO6KRmkpKe88QqFDcQucLAV0ve0YIsML6cGBtln5CZ8uIEcYj6PHNPKzNKmwNLW4pxttCeHdPiOHHgimbqewFxxHKqpdkOJFEccnETvr2H-ltWGKxYK_SVMmOyb-qFZQJiiGh_NjuoOZCaiXKSN1Odf4fVXnczpHitx9K_aiBHRpsDClF9A9DUmJ20TOH6JkSPbOPnqGl6c3j9Ty0_Mka_w3789TH</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3079187627</pqid></control><display><type>article</type><title>Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke</title><source>ProQuest - Publicly Available Content Database</source><source>PubMed Central</source><creator>Chen, Wenxia ; Zhang, Hanqing ; Li, Zhenzhen ; Deng, Qiwen ; Wang, Meng ; Chen, Yingbin ; Zhang, Yuan</creator><creatorcontrib>Chen, Wenxia ; Zhang, Hanqing ; Li, Zhenzhen ; Deng, Qiwen ; Wang, Meng ; Chen, Yingbin ; Zhang, Yuan</creatorcontrib><description>Edaravone dexborneol has been reported as an effective neuroprotective agent in the treatment of acute ischemic stroke (AIS). This study aimed at investigating the impact of edaravone dexborneol on functional outcomes and systematic inflammatory response in AIS patient.
All participants were recruited from the AISRNA study (registered 21/11/2019, NCT04175691 [ClinicalTrials.gov]) between January 2022 and December 2022. The AIS patients were divided into two groups based on whether they received the treatment of edaravone dexborneol (37.5 mg/12 hours, IV) within 48 h after stroke onset. Inflammatory response was determined by detecting levels of cytokines (interleukin-2 [IL-2], IL-4, IL-5, IL-8, IL-6, IL-10, IL-12p70, IL-17, tumor necrosis factor-α [TNF-α], interferon-γ [IFN-γ], IFN-α, and IL-1β) within 14 days after stroke onset.
Eighty-five AIS patients were included from the AISRNA study. Patients treated with edaravone dexborneol showed a significantly higher proportion of modified Rankin Scale score < 2 compared to those who did not receive this treatment (70.7% versus 47.8%; P = 0.031). Furthermore, individuals receiving edaravone dexborneol injection exhibited lower expression levels of interleukin (IL)-1β, IL-6, and IL-17, along with higher levels of IL-4 and IL-10 expression during the acute phase of ischemic stroke (P < 0.05). These trends were not observed for IL-2, IL-5, IL-8, IL-12p70, tumor necrosis factor-α, interferon-γ [IFN-γ], and IFN-α (P > 0.05).
Treatment with edaravone dexborneol resulted in a favorable functional outcome at 90 days post-stroke onset when compared to patients without this intervention; it also suppressed proinflammatory factors expression while increasing anti-inflammatory factors levels.
ClinicalTrials.gov NCT04175691. Registered November 21, 2019, https://www.
gov/ct2/show/NCT04175691 .</description><identifier>ISSN: 1471-2377</identifier><identifier>EISSN: 1471-2377</identifier><identifier>DOI: 10.1186/s12883-024-03712-1</identifier><identifier>PMID: 38902691</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Acute ischemic stroke ; Aged ; Analysis ; Brain damage ; Care and treatment ; Clinical outcomes ; Complications and side effects ; Cytokines - metabolism ; Edaravone - administration & dosage ; Edaravone - pharmacology ; Edaravone - therapeutic use ; Edaravone dexborneol ; Female ; Functional outcome ; Humans ; Inflammation ; Inflammation - drug therapy ; Inflammatory response ; Interleukin ; Interleukin 10 ; Interleukin 12 ; Interleukin 17 ; Interleukin 2 ; Interleukin 4 ; Interleukin 5 ; Interleukin 6 ; Interleukin 8 ; Interleukins ; Ischemia ; Ischemic Stroke - drug therapy ; Male ; Middle Aged ; Modified Rankin Scale ; Mortality ; Neuroprotection ; Neuroprotective Agents - administration & dosage ; Neuroprotective Agents - therapeutic use ; Prevention ; Risk factors ; Stroke ; Stroke (Disease) ; Treatment Outcome ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α ; α-Interferon ; γ-Interferon</subject><ispartof>BMC neurology, 2024-06, Vol.24 (1), p.209-8, Article 209</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c445t-348545505927d9e2efcba004980e74c0dcdf013a452589abbfe69546946b2d433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11188235/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3079187627?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38902691$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Wenxia</creatorcontrib><creatorcontrib>Zhang, Hanqing</creatorcontrib><creatorcontrib>Li, Zhenzhen</creatorcontrib><creatorcontrib>Deng, Qiwen</creatorcontrib><creatorcontrib>Wang, Meng</creatorcontrib><creatorcontrib>Chen, Yingbin</creatorcontrib><creatorcontrib>Zhang, Yuan</creatorcontrib><title>Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke</title><title>BMC neurology</title><addtitle>BMC Neurol</addtitle><description>Edaravone dexborneol has been reported as an effective neuroprotective agent in the treatment of acute ischemic stroke (AIS). This study aimed at investigating the impact of edaravone dexborneol on functional outcomes and systematic inflammatory response in AIS patient.
All participants were recruited from the AISRNA study (registered 21/11/2019, NCT04175691 [ClinicalTrials.gov]) between January 2022 and December 2022. The AIS patients were divided into two groups based on whether they received the treatment of edaravone dexborneol (37.5 mg/12 hours, IV) within 48 h after stroke onset. Inflammatory response was determined by detecting levels of cytokines (interleukin-2 [IL-2], IL-4, IL-5, IL-8, IL-6, IL-10, IL-12p70, IL-17, tumor necrosis factor-α [TNF-α], interferon-γ [IFN-γ], IFN-α, and IL-1β) within 14 days after stroke onset.
Eighty-five AIS patients were included from the AISRNA study. Patients treated with edaravone dexborneol showed a significantly higher proportion of modified Rankin Scale score < 2 compared to those who did not receive this treatment (70.7% versus 47.8%; P = 0.031). Furthermore, individuals receiving edaravone dexborneol injection exhibited lower expression levels of interleukin (IL)-1β, IL-6, and IL-17, along with higher levels of IL-4 and IL-10 expression during the acute phase of ischemic stroke (P < 0.05). These trends were not observed for IL-2, IL-5, IL-8, IL-12p70, tumor necrosis factor-α, interferon-γ [IFN-γ], and IFN-α (P > 0.05).
Treatment with edaravone dexborneol resulted in a favorable functional outcome at 90 days post-stroke onset when compared to patients without this intervention; it also suppressed proinflammatory factors expression while increasing anti-inflammatory factors levels.
ClinicalTrials.gov NCT04175691. Registered November 21, 2019, https://www.
gov/ct2/show/NCT04175691 .</description><subject>Acute ischemic stroke</subject><subject>Aged</subject><subject>Analysis</subject><subject>Brain damage</subject><subject>Care and treatment</subject><subject>Clinical outcomes</subject><subject>Complications and side effects</subject><subject>Cytokines - metabolism</subject><subject>Edaravone - administration & dosage</subject><subject>Edaravone - pharmacology</subject><subject>Edaravone - therapeutic use</subject><subject>Edaravone dexborneol</subject><subject>Female</subject><subject>Functional outcome</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation - drug therapy</subject><subject>Inflammatory response</subject><subject>Interleukin</subject><subject>Interleukin 10</subject><subject>Interleukin 12</subject><subject>Interleukin 17</subject><subject>Interleukin 2</subject><subject>Interleukin 4</subject><subject>Interleukin 5</subject><subject>Interleukin 6</subject><subject>Interleukin 8</subject><subject>Interleukins</subject><subject>Ischemia</subject><subject>Ischemic Stroke - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Modified Rankin Scale</subject><subject>Mortality</subject><subject>Neuroprotection</subject><subject>Neuroprotective Agents - administration & dosage</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Prevention</subject><subject>Risk factors</subject><subject>Stroke</subject><subject>Stroke (Disease)</subject><subject>Treatment Outcome</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><subject>α-Interferon</subject><subject>γ-Interferon</subject><issn>1471-2377</issn><issn>1471-2377</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk9v1DAQxSMEoqXwBTigSFy4pPhfYvuEqqpApUpc4GxN7PFuShIvtrPQb493t5QuQjk4Gb_5RTPvVdVrSs4pVd37RJlSvCFMNIRLyhr6pDqlQtKGcSmfPno_qV6kdEsIlUrQ59UJV5qwTtPTanvlPdqc6uBrdBBhG2asHf7qQ5wxjHWYa7_MNg9hhvK1ZBsmrGF29TD7EaYJcoh3dcS0CXPCUq03kAecC_PnkNc12CWXcrJrnAZbpxzDd3xZPfMwJnx1f55V3z5efb383Nx8-XR9eXHTWCHa3HChWtG2pNVMOo0Mve2BEKEVQSkscdZ5QjmIlrVKQ9977HQrOi26njnB-Vl1feC6ALdmE4cJ4p0JMJh9IcSVgZgHO6KRmkpKe88QqFDcQucLAV0ve0YIsML6cGBtln5CZ8uIEcYj6PHNPKzNKmwNLW4pxttCeHdPiOHHgimbqewFxxHKqpdkOJFEccnETvr2H-ltWGKxYK_SVMmOyb-qFZQJiiGh_NjuoOZCaiXKSN1Odf4fVXnczpHitx9K_aiBHRpsDClF9A9DUmJ20TOH6JkSPbOPnqGl6c3j9Ty0_Mka_w3789TH</recordid><startdate>20240620</startdate><enddate>20240620</enddate><creator>Chen, Wenxia</creator><creator>Zhang, Hanqing</creator><creator>Li, Zhenzhen</creator><creator>Deng, Qiwen</creator><creator>Wang, Meng</creator><creator>Chen, Yingbin</creator><creator>Zhang, Yuan</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240620</creationdate><title>Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke</title><author>Chen, Wenxia ; Zhang, Hanqing ; Li, Zhenzhen ; Deng, Qiwen ; Wang, Meng ; Chen, Yingbin ; Zhang, Yuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-348545505927d9e2efcba004980e74c0dcdf013a452589abbfe69546946b2d433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acute ischemic stroke</topic><topic>Aged</topic><topic>Analysis</topic><topic>Brain damage</topic><topic>Care and treatment</topic><topic>Clinical outcomes</topic><topic>Complications and side effects</topic><topic>Cytokines - metabolism</topic><topic>Edaravone - administration & dosage</topic><topic>Edaravone - pharmacology</topic><topic>Edaravone - therapeutic use</topic><topic>Edaravone dexborneol</topic><topic>Female</topic><topic>Functional outcome</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation - drug therapy</topic><topic>Inflammatory response</topic><topic>Interleukin</topic><topic>Interleukin 10</topic><topic>Interleukin 12</topic><topic>Interleukin 17</topic><topic>Interleukin 2</topic><topic>Interleukin 4</topic><topic>Interleukin 5</topic><topic>Interleukin 6</topic><topic>Interleukin 8</topic><topic>Interleukins</topic><topic>Ischemia</topic><topic>Ischemic Stroke - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Modified Rankin Scale</topic><topic>Mortality</topic><topic>Neuroprotection</topic><topic>Neuroprotective Agents - administration & dosage</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Prevention</topic><topic>Risk factors</topic><topic>Stroke</topic><topic>Stroke (Disease)</topic><topic>Treatment Outcome</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><topic>α-Interferon</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Wenxia</creatorcontrib><creatorcontrib>Zhang, Hanqing</creatorcontrib><creatorcontrib>Li, Zhenzhen</creatorcontrib><creatorcontrib>Deng, Qiwen</creatorcontrib><creatorcontrib>Wang, Meng</creatorcontrib><creatorcontrib>Chen, Yingbin</creatorcontrib><creatorcontrib>Zhang, Yuan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Wenxia</au><au>Zhang, Hanqing</au><au>Li, Zhenzhen</au><au>Deng, Qiwen</au><au>Wang, Meng</au><au>Chen, Yingbin</au><au>Zhang, Yuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke</atitle><jtitle>BMC neurology</jtitle><addtitle>BMC Neurol</addtitle><date>2024-06-20</date><risdate>2024</risdate><volume>24</volume><issue>1</issue><spage>209</spage><epage>8</epage><pages>209-8</pages><artnum>209</artnum><issn>1471-2377</issn><eissn>1471-2377</eissn><abstract>Edaravone dexborneol has been reported as an effective neuroprotective agent in the treatment of acute ischemic stroke (AIS). This study aimed at investigating the impact of edaravone dexborneol on functional outcomes and systematic inflammatory response in AIS patient.
All participants were recruited from the AISRNA study (registered 21/11/2019, NCT04175691 [ClinicalTrials.gov]) between January 2022 and December 2022. The AIS patients were divided into two groups based on whether they received the treatment of edaravone dexborneol (37.5 mg/12 hours, IV) within 48 h after stroke onset. Inflammatory response was determined by detecting levels of cytokines (interleukin-2 [IL-2], IL-4, IL-5, IL-8, IL-6, IL-10, IL-12p70, IL-17, tumor necrosis factor-α [TNF-α], interferon-γ [IFN-γ], IFN-α, and IL-1β) within 14 days after stroke onset.
Eighty-five AIS patients were included from the AISRNA study. Patients treated with edaravone dexborneol showed a significantly higher proportion of modified Rankin Scale score < 2 compared to those who did not receive this treatment (70.7% versus 47.8%; P = 0.031). Furthermore, individuals receiving edaravone dexborneol injection exhibited lower expression levels of interleukin (IL)-1β, IL-6, and IL-17, along with higher levels of IL-4 and IL-10 expression during the acute phase of ischemic stroke (P < 0.05). These trends were not observed for IL-2, IL-5, IL-8, IL-12p70, tumor necrosis factor-α, interferon-γ [IFN-γ], and IFN-α (P > 0.05).
Treatment with edaravone dexborneol resulted in a favorable functional outcome at 90 days post-stroke onset when compared to patients without this intervention; it also suppressed proinflammatory factors expression while increasing anti-inflammatory factors levels.
ClinicalTrials.gov NCT04175691. Registered November 21, 2019, https://www.
gov/ct2/show/NCT04175691 .</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>38902691</pmid><doi>10.1186/s12883-024-03712-1</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2377 |
| ispartof | BMC neurology, 2024-06, Vol.24 (1), p.209-8, Article 209 |
| issn | 1471-2377 1471-2377 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_791711bf2ea1483ca6fd43edb7b200a2 |
| source | ProQuest - Publicly Available Content Database; PubMed Central |
| subjects | Acute ischemic stroke Aged Analysis Brain damage Care and treatment Clinical outcomes Complications and side effects Cytokines - metabolism Edaravone - administration & dosage Edaravone - pharmacology Edaravone - therapeutic use Edaravone dexborneol Female Functional outcome Humans Inflammation Inflammation - drug therapy Inflammatory response Interleukin Interleukin 10 Interleukin 12 Interleukin 17 Interleukin 2 Interleukin 4 Interleukin 5 Interleukin 6 Interleukin 8 Interleukins Ischemia Ischemic Stroke - drug therapy Male Middle Aged Modified Rankin Scale Mortality Neuroprotection Neuroprotective Agents - administration & dosage Neuroprotective Agents - therapeutic use Prevention Risk factors Stroke Stroke (Disease) Treatment Outcome Tumor necrosis factor-TNF Tumor necrosis factor-α α-Interferon γ-Interferon |
| title | Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T12%3A25%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20edaravone%20dexborneol%20on%20functional%20outcome%20and%20inflammatory%20response%20in%20patients%20with%20acute%20ischemic%20stroke&rft.jtitle=BMC%20neurology&rft.au=Chen,%20Wenxia&rft.date=2024-06-20&rft.volume=24&rft.issue=1&rft.spage=209&rft.epage=8&rft.pages=209-8&rft.artnum=209&rft.issn=1471-2377&rft.eissn=1471-2377&rft_id=info:doi/10.1186/s12883-024-03712-1&rft_dat=%3Cgale_doaj_%3EA798491767%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c445t-348545505927d9e2efcba004980e74c0dcdf013a452589abbfe69546946b2d433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3079187627&rft_id=info:pmid/38902691&rft_galeid=A798491767&rfr_iscdi=true |